Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
Sage Therapeutics (NASDAQ: SAGE) will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET. Investors can access a live webcast on the company's investor page, with a replay available two hours after the event for 30 days. Sage Therapeutics is focused on developing innovative therapies to improve brain health and transform the treatment of debilitating brain disorders. For more information, visit www.sagerx.com.
- None.
- None.
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET.
A live webcast of each presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005173/en/
FAQ
What is the date and time of Sage Therapeutics' participation in the CNS Forum?
Where can I watch the live webcast of Sage Therapeutics at the CNS Forum?
Will there be a replay of Sage Therapeutics' presentation at the CNS Forum?
What is the focus of Sage Therapeutics as a biopharmaceutical company?